PLIANT THERAPEUTICS, INC. 8K

Pliant Therapeutics announced Q1 2026 results showing significantly lower expenses and net loss, initiated the FORTIFY Phase 1b trial of PLN-101095 and presented positive updated Phase 1 data at AACR 2026, while stating its cash runway extends into the second half of 2028.

Pliant Therapeutics, Inc. reported its first quarter 2026 financial results and provided a corporate update, highlighting initiation and first patient dosing in April 2026 of FORTIFY, a Phase 1b indication expansion trial of its lead integrin-targeting oncology candidate PLN-101095 in ICI‑refractory solid tumors, along with encouraging updated Phase 1 data presented at AACR 2026 showing confirmed responses and biomarker changes when PLN-101095 was combined with pembrolizumab. The company also described ongoing preclinical work on its integrin-targeted delivery platform for siRNA payloads, and disclosed a sharp reduction in operating expenses and net loss versus the prior-year quarter following the 2025 termination of bexotegrast development in IPF, reporting Q1 2026 R&D expenses of $13.6 million, G&A expenses of $8.2 million, a net loss of $20.0 million, and cash, cash equivalents and short-term investments of $172.4 million, which it believes are sufficient to fund operations into the second half of 2028.

Filing Facts

CIK

1746473

Ticker

-

Form

8K

Source Type

sec

Accession

0001746473-26-000088

Alert Tier

6